A strategic cooperation agreement has been signed between GPHL and Sichuan Province, mainly about further cooperation in TCM, health care, commerce, and medical treatment.
The visit took place after GPHL signed two strategic cooperation agreements with Gansu Province during the Gansu Investment Promotion Conference at Zhudao Hotel in Guangzhou on April 24.
China’s leading pharmaceuticals enterprise GPHL reported an operating income of 20.954 billion RMB in 2017, up 4.58% year-on-year, and a net profit of 2.062 billion RMB, up 36.71%.
On the evening of Jan. 1, GPHL announced that it has received permission from the China Food and Drug Administration to conduct clinical trials with their class 1.1 new drug Ceftriamidine Sodium.
During the Conference, GPHL conferred with international pharmaceutical giants including Teva Pharmaceutical Industries Limited, the largest generic drug manufacturer and Walgreens Boots Alliance.
Recently, GPHL has made exciting breakthroughs in terms of TCM modernization and internationalization. Baiyunshan Hanfang Botanical Anti-tumor Drug has been CEP approved by EDOM.